Interaction between hsp90 and Soluble Guanylate Cyclase: Physiological Significance and Mapping of the Domains Mediating Binding

C. Gerasimou, Z. Zhou, C. Roussos, Andreas Papapetropoulos

Research output: Contribution to journalArticle

Abstract

Heat shock protein 90 (hsp90) regulates stability and function of many client proteins including members of the NO-cGMP signaling pathway. Soluble guanylate cyclase (sGC), which is the main intracellular receptor of NO, was recently reported to be an hsp90 interacting partner, however, the interaction between the two proteins remains to be characterized and functionally evaluated. In the present study, we show that hsp90 binds to both subunits of the most commonly found sGC isoform, α1β1. Characterization of the region of hsp90 required to bind each subunit in immuno-precipitation experiments, revealed that residues 310-456 of hsp90 interact with both α1 and β1. The region of β1 responsible for binding to hsp90 was mapped in in vitro binding assays and was found to lie between residues 200-408. The importance of the hsp90-sGC interaction was investigated by treating rat smooth muscle cells (RASMC) with the hsp90 inhibitors radicicol (RAD) and geldanamycin (GA) for 1, 24 and 48 hours and determining both sGC activity and protein levels. Long-term (24 or 48 hr) inhibition of hsp90 resulted in a strong decrease of both α1 and β1 protein levels, as well as sGC activity.

Original languageEnglish (US)
Pages (from-to)112-114
Number of pages3
JournalReview of Clinical Pharmacology and Pharmacokinetics, International Edition
Volume18
Issue number1
StatePublished - Mar 19 2004
Externally publishedYes

Fingerprint

HSP90 Heat-Shock Proteins
Proteins
Soluble Guanylyl Cyclase
Smooth Muscle Myocytes
Protein Isoforms

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{924bfc23b1474ef0a309f92a193538ed,
title = "Interaction between hsp90 and Soluble Guanylate Cyclase: Physiological Significance and Mapping of the Domains Mediating Binding",
abstract = "Heat shock protein 90 (hsp90) regulates stability and function of many client proteins including members of the NO-cGMP signaling pathway. Soluble guanylate cyclase (sGC), which is the main intracellular receptor of NO, was recently reported to be an hsp90 interacting partner, however, the interaction between the two proteins remains to be characterized and functionally evaluated. In the present study, we show that hsp90 binds to both subunits of the most commonly found sGC isoform, α1β1. Characterization of the region of hsp90 required to bind each subunit in immuno-precipitation experiments, revealed that residues 310-456 of hsp90 interact with both α1 and β1. The region of β1 responsible for binding to hsp90 was mapped in in vitro binding assays and was found to lie between residues 200-408. The importance of the hsp90-sGC interaction was investigated by treating rat smooth muscle cells (RASMC) with the hsp90 inhibitors radicicol (RAD) and geldanamycin (GA) for 1, 24 and 48 hours and determining both sGC activity and protein levels. Long-term (24 or 48 hr) inhibition of hsp90 resulted in a strong decrease of both α1 and β1 protein levels, as well as sGC activity.",
author = "C. Gerasimou and Z. Zhou and C. Roussos and Andreas Papapetropoulos",
year = "2004",
month = "3",
day = "19",
language = "English (US)",
volume = "18",
pages = "112--114",
journal = "Review of Clinical Pharmacology and Pharmacokinetics, International Edition",
issn = "1011-6583",
publisher = "PHARMAKON-Press",
number = "1",

}

TY - JOUR

T1 - Interaction between hsp90 and Soluble Guanylate Cyclase

T2 - Physiological Significance and Mapping of the Domains Mediating Binding

AU - Gerasimou, C.

AU - Zhou, Z.

AU - Roussos, C.

AU - Papapetropoulos, Andreas

PY - 2004/3/19

Y1 - 2004/3/19

N2 - Heat shock protein 90 (hsp90) regulates stability and function of many client proteins including members of the NO-cGMP signaling pathway. Soluble guanylate cyclase (sGC), which is the main intracellular receptor of NO, was recently reported to be an hsp90 interacting partner, however, the interaction between the two proteins remains to be characterized and functionally evaluated. In the present study, we show that hsp90 binds to both subunits of the most commonly found sGC isoform, α1β1. Characterization of the region of hsp90 required to bind each subunit in immuno-precipitation experiments, revealed that residues 310-456 of hsp90 interact with both α1 and β1. The region of β1 responsible for binding to hsp90 was mapped in in vitro binding assays and was found to lie between residues 200-408. The importance of the hsp90-sGC interaction was investigated by treating rat smooth muscle cells (RASMC) with the hsp90 inhibitors radicicol (RAD) and geldanamycin (GA) for 1, 24 and 48 hours and determining both sGC activity and protein levels. Long-term (24 or 48 hr) inhibition of hsp90 resulted in a strong decrease of both α1 and β1 protein levels, as well as sGC activity.

AB - Heat shock protein 90 (hsp90) regulates stability and function of many client proteins including members of the NO-cGMP signaling pathway. Soluble guanylate cyclase (sGC), which is the main intracellular receptor of NO, was recently reported to be an hsp90 interacting partner, however, the interaction between the two proteins remains to be characterized and functionally evaluated. In the present study, we show that hsp90 binds to both subunits of the most commonly found sGC isoform, α1β1. Characterization of the region of hsp90 required to bind each subunit in immuno-precipitation experiments, revealed that residues 310-456 of hsp90 interact with both α1 and β1. The region of β1 responsible for binding to hsp90 was mapped in in vitro binding assays and was found to lie between residues 200-408. The importance of the hsp90-sGC interaction was investigated by treating rat smooth muscle cells (RASMC) with the hsp90 inhibitors radicicol (RAD) and geldanamycin (GA) for 1, 24 and 48 hours and determining both sGC activity and protein levels. Long-term (24 or 48 hr) inhibition of hsp90 resulted in a strong decrease of both α1 and β1 protein levels, as well as sGC activity.

UR - http://www.scopus.com/inward/record.url?scp=1542350023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542350023&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:1542350023

VL - 18

SP - 112

EP - 114

JO - Review of Clinical Pharmacology and Pharmacokinetics, International Edition

JF - Review of Clinical Pharmacology and Pharmacokinetics, International Edition

SN - 1011-6583

IS - 1

ER -